DK0896586T3 - ErbB3 antistoffer - Google Patents

ErbB3 antistoffer

Info

Publication number
DK0896586T3
DK0896586T3 DK97908923T DK97908923T DK0896586T3 DK 0896586 T3 DK0896586 T3 DK 0896586T3 DK 97908923 T DK97908923 T DK 97908923T DK 97908923 T DK97908923 T DK 97908923T DK 0896586 T3 DK0896586 T3 DK 0896586T3
Authority
DK
Denmark
Prior art keywords
erbb3
erbb2
heregulin
ability
cell
Prior art date
Application number
DK97908923T
Other languages
English (en)
Other versions
DK0896586T4 (da
Inventor
Robert Akita
Mark Sliwkowski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24500380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0896586(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0896586T3 publication Critical patent/DK0896586T3/da
Publication of DK0896586T4 publication Critical patent/DK0896586T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
DK97908923.2T 1996-03-27 1997-03-07 ErbB3-antistoffer. DK0896586T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62403696A 1996-03-27 1996-03-27
PCT/US1997/003546 WO1997035885A1 (en) 1996-03-27 1997-03-07 ErbB3 ANTIBODIES

Publications (2)

Publication Number Publication Date
DK0896586T3 true DK0896586T3 (da) 2007-02-19
DK0896586T4 DK0896586T4 (da) 2015-08-24

Family

ID=24500380

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97908923.2T DK0896586T4 (da) 1996-03-27 1997-03-07 ErbB3-antistoffer.

Country Status (15)

Country Link
EP (2) EP0896586B2 (da)
JP (1) JP3925943B2 (da)
CN (1) CN1214044C (da)
AT (1) ATE342283T1 (da)
AU (1) AU727082B2 (da)
BR (1) BR9708343A (da)
CA (1) CA2246429C (da)
DE (1) DE69736806T3 (da)
DK (1) DK0896586T4 (da)
ES (1) ES2274537T5 (da)
IL (2) IL126303A (da)
NZ (1) NZ331360A (da)
PT (1) PT896586E (da)
WO (1) WO1997035885A1 (da)
ZA (1) ZA972554B (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
NZ517150A (en) 1999-08-27 2005-01-28 Genentech Inc Dosages for treatment with anti-ErbB2 antibodies
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
AU2008200654B2 (en) * 2001-08-09 2010-04-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Inhibitors of HER3 activity
JP4660094B2 (ja) 2002-03-26 2011-03-30 ゼンサン （シャンハイ） サイ−テク． リミテッド 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物
DK2263691T3 (da) 2002-07-15 2012-10-22 Hoffmann La Roche Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4)
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
JP5656406B2 (ja) 2006-11-28 2015-01-21 ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツングＵ３ Ｐｈａｒｍａ ＧｍｂＨ 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３
SI2129396T1 (sl) * 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Protitelesa proti ErbB3 in njihove uporabe
EA022884B1 (ru) * 2008-08-15 2016-03-31 Мерримак Фармасьютикалз, Инк. СПОСОБ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ С ИСПОЛЬЗОВАНИЕМ АНТИ-ErbB3 АНТИТЕЛА
CN102378768A (zh) 2009-04-07 2012-03-14 罗氏格黎卡特股份公司 双特异性抗-ErbB-3/抗-c-Met抗体
RS56741B1 (sr) 2009-11-13 2018-03-30 Daiichi Sankyo Europe Gmbh Materijal i postupci za lečenje ili prevenciju bolesti povezanih sa her-3
KR20120123299A (ko) 2009-12-04 2012-11-08 제넨테크, 인크. 다중특이적 항체, 항체 유사체, 조성물 및 방법
MY161909A (en) 2009-12-22 2017-05-15 Roche Glycart Ag Anti-her3 antibodies and uses thereof
DK2544680T3 (da) 2010-03-11 2015-04-27 Merrimack Pharmaceuticals Inc Anvendelse af erbb3-hæmmere i behandlingen af triple-negativ brystcancer
SG184452A1 (en) * 2010-04-09 2012-11-29 Aveo Pharmaceuticals Inc Anti-erbb3 antibodies
JP6082344B2 (ja) 2010-05-27 2017-02-15 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
CN107253992B (zh) 2010-05-27 2022-03-11 根马布股份公司 针对her2的单克隆抗体
US9011863B2 (en) 2010-07-09 2015-04-21 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
JP6186277B2 (ja) 2010-11-01 2017-08-23 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 抗ｈｅｒ３抗体および組成物
HUE034276T2 (en) 2011-04-19 2018-02-28 Merrimack Pharmaceuticals Inc Bispecific anti-IGF-1R and anti-ErbB3 antibodies
CA2832389A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
ES2694153T3 (es) 2011-09-30 2018-12-18 Regeneron Pharmaceuticals, Inc. Anticuerpos anti-ErbB3 y usos de los mismos
WO2013052745A1 (en) * 2011-10-06 2013-04-11 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-erbb3 antibodies
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2013071058A1 (en) * 2011-11-09 2013-05-16 The Uab Research Foundation Her3 antibodies and uses thereof
CN104093743B (zh) 2011-11-23 2018-04-24 医学免疫有限责任公司 特异于her3的结合分子及其用途
EP3590538A1 (en) * 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
US9725511B2 (en) * 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
AU2013343667A1 (en) 2012-11-08 2015-04-02 F. Hoffmann-La Roche Ag HER3 antigen binding proteins binding to the beta-hairpin of HER3
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
BR112016024457A2 (pt) 2014-05-14 2018-01-23 Hoffmann La Roche anticorpo isolado, imunoconjugado, uso do anticorpo, formulação farmacêutica, ácido nucleico isolado, célula hospedeira e método de produção de um anticorpo
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
TW202227504A (zh) * 2020-10-15 2022-07-16 大陸商上海翰森生物醫藥科技有限公司 抗ｅｒｂｂ３抗體或其抗原結合片段及其醫藥用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
DE69333807T2 (de) * 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
WO1993021319A1 (en) * 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
AU6527894A (en) * 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis

Also Published As

Publication number Publication date
DK0896586T4 (da) 2015-08-24
WO1997035885A1 (en) 1997-10-02
EP1728802A3 (en) 2006-12-13
CA2246429A1 (en) 1997-10-02
EP0896586A1 (en) 1999-02-17
CA2246429C (en) 2007-07-24
EP1728802A2 (en) 2006-12-06
IL126303A (en) 2002-05-23
DE69736806D1 (de) 2006-11-23
EP0896586B1 (en) 2006-10-11
ES2274537T3 (es) 2007-05-16
DE69736806T3 (de) 2015-10-08
NZ331360A (en) 2000-03-27
AU2071197A (en) 1997-10-17
ATE342283T1 (de) 2006-11-15
CN1214044C (zh) 2005-08-10
BR9708343A (pt) 1999-08-03
CN1214695A (zh) 1999-04-21
JP3925943B2 (ja) 2007-06-06
JP2000508526A (ja) 2000-07-11
DE69736806T2 (de) 2007-08-09
ZA972554B (en) 1998-09-25
IL126303A0 (en) 1999-05-09
ES2274537T5 (es) 2015-09-14
EP0896586B2 (en) 2015-05-20
AU727082B2 (en) 2000-11-30
PT896586E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
DK0896586T3 (da) ErbB3 antistoffer
EP1071460A4 (en) INTERNALIZING ERB2 ANTIBODIES
EP0754225A4 (en) HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
EP0930366A3 (en) Binding domains in delta proteins
ATE486937T1 (de) Chimärische heteromultimerische adhesine
PT1135498E (pt) Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
CY1110877T1 (el) Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
IL223048A (en) Variant peptides linking fcrn with increased affinity and method for their production
DE69429925D1 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID
NO961151D0 (no) Antistoffer mot CD40
EP1695986A3 (en) Anti-erb B2 antibodies
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
IL191077A0 (en) An isolated antibody which binds to the n-terminal domain of gamma-heregulin and methods using it
EP1813672A3 (en) Transgenic non-human animals capable of producing heterologous antibodies
CA2135208A1 (en) Immunoglobulin binding proteins derived from l protein and their uses
WO1996027665A3 (en) Neuron-restrictive silencer factor proteins
ATE217086T1 (de) Herstellung von photoprotein konjugaten und verfahren zu ihrer verwendung
NZ336781A (en) Fibronectin binding protein compositions, antibodies thereto, and methods of use
EP1510579A3 (en) Use of heregulin as an epithelial cell growth factor
DE69634077D1 (de) Haemophilus adhäsionsproteinen
CA2589421A1 (en) Erbb3 antibodies
AU4375493A (en) Isolated protein receptors, antibodies which bind thereto, nucleic acid sequence coding therefor, and uses thereof
DE59310280D1 (de) Verfahren zur Herstellung von Konjugaten aus einem spezifischen Bindungspartner und einem kohlenhydrathaltigen Protein
AU2726388A (en) Determination method, use and components
CA2180957A1 (en) Cloning and recombinant production of crf receptor(s)